Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM3 | P20309 | 9/20 | 0.67 |
| ▸ | CHRM2 | P08172 | 5/20 | 0.44 |
| ▸ | CHRM1 | P11229 | 5/20 | 0.44 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.40 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.40 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.33 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2842262 | 1.00 | CHRM3 (0.67) | CHRM3CHRM2CHRM1APOBEC3AAPOBEC3G | |
| SCHEMBL138472 | 0.85 | CHRM3 (0.68) | CHRM3CHRM2CHRM1APOBEC3AAPOBEC3G | |
| SCHEMBL138471 | 0.85 | CHRM3 (0.68) | CHRM3CHRM2CHRM1APOBEC3AAPOBEC3G | |
| Bromide SCHEMBL141730 | 0.81 | CHRM3 (1.00) | CHRM3CHRM2CHRM1APOBEC3AAPOBEC3G | |
| Bromide SCHEMBL141731 | 0.81 | CHRM3 (1.00) | CHRM3CHRM2CHRM1APOBEC3AAPOBEC3G | |
| Bromide SCHEMBL4166137 | 0.76 | CHRM3 (0.88) | CHRM3CHRM2CHRM1APOBEC3AAPOBEC3G | |
| Bromide SCHEMBL4166138 | 0.76 | CHRM3 (0.88) | CHRM3CHRM2CHRM1APOBEC3AAPOBEC3G | |
| SCHEMBL3910006 | 0.70 | CHRM3 (0.47) | CHRM3APOBEC3AAPOBEC3GPTGS2LMNA | |
| Bromide SCHEMBL5039534 | 0.70 | CHRM3 (0.74) | CHRM3CHRM2CHRM1APOBEC3AAPOBEC3G | |
| Bromide SCHEMBL5039532 | 0.70 | CHRM3 (0.74) | CHRM3CHRM2CHRM1APOBEC3AAPOBEC3G |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8071584-B2 | Indole carboxamides as IKK2 inhibitors | GLAXOSMITHKLINE LLC (US) | 2011-12-06 | — | — | US | disclosed |
| US-20100130468-A1 | INDOLE CARBOXAMIDES AS IKK2 INHIBITORS | GLAXOSMITHKLINE LLC | 2010-05-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100130468-A1 | INDOLE CARBOXAMIDES AS IKK2 INHIBITORS | IDO2, IDO1, NFKBIA | CHRM3 207/4885CHRM2 100/4885CHRM1 281/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.